News & Analysis as of

Information Technology Artificial Intelligence Supply Chain

Guidepost Solutions LLC

Unlocking Opportunity: Navigating the New Data Center Validated End User Program

Recently, the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) published a significant interim final rule (IFR) that has created both challenges and exciting opportunities for these operators. This IFR...more

Foley & Lardner LLP

Strategies for the Tech Sector in 2024

Foley & Lardner LLP on

After two very difficult years in the tech sector, everyone is hoping for a comeback. We are looking at a more positive economic climate, the prospect of interest rates dropping, and there is much less talk of a recession...more

HaystackID

[Webcast Transcript] M365 for Law Firms and Lawyers: Purview Premium eDiscovery and Security, Capabilities and War Stories

HaystackID on

Editor’s Note: In a rapidly evolving technological landscape, understanding the capabilities and limitations of platforms like Microsoft 365 (M365) is crucial for law firms, especially in the realms of eDiscovery and...more

Foley Hoag LLP - Global Business and Human...

A Human Rights Impact Assessment of Microsoft's Enterprise Cloud and AI Technologies Licensed to U.S. Law Enforcement Agencies

Microsoft is one of the world’s leading technology companies. Its products and technologies are in offices, classrooms, and homes. Additionally, governments use them to help conduct vital public services. Microsoft is also...more

Foley & Lardner LLP

AI & IOT integration in IBM’s Blockchain Supply Management as a Service (SPaaS)!

Foley & Lardner LLP on

Computerworld reported that IBM’s new SPaaS “allows distributors, manufacturers and retailers to integrate their own data and networks – as well as those of their suppliers – onto a Hyperledger-based blockchain to track and...more

Hogan Lovells

Life Sciences and Health Care Horizons - 2019

Hogan Lovells on

Innovation in the life sciences and health care industries is occurring at a dizzying pace. Five years ago, anti-PD-1 antibodies from Merck and BMS had yet to be approved, CAR-T therapies were still in small-scale clinical...more

6 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide